Dec 30 (Reuters) - Pfizer:
* Provides U.S. regulatory update on Prevnar 13(TM) vaccine
* Says review will continue beyond the prescription drug user fee action date
of December 30, 2009
* Says FDA has not yet completed its review of the biologics license
application for Prevnar 13
* Says further pediatric regulatory filings for Prevnar 13 are in advanced
stages of review in various countries
* Says vaccine is being studied in global phase 3 clinical trials in adults,
with regulatory submissions expected in 2010
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Provides U.S. regulatory update on Prevnar 13(TM) vaccine
* Says review will continue beyond the prescription drug user fee action date
of December 30, 2009
* Says FDA has not yet completed its review of the biologics license
application for Prevnar 13
* Says further pediatric regulatory filings for Prevnar 13 are in advanced
stages of review in various countries
* Says vaccine is being studied in global phase 3 clinical trials in adults,
with regulatory submissions expected in 2010
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.